Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma
Another Boost For Blockbuster
While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.
You may also be interested in...
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.
Several high-profile products including Dupixent gain approvals in China.